March 2021

Risk of COVID-19 from aerosols to healthcare workers: Study – Express Healthcare

Read Article New research published in Anaesthesia (a journal of the Association of Anaesthetists) challenges the guidance that special aerosol precautions are only needed when using oxygen therapies for COVID-19 patients, and raises concerns about the safety of staff and patients in hospital wards if they are not protected from infectious aerosols. The study set out […]

Risk of COVID-19 from aerosols to healthcare workers: Study – Express Healthcare Read More »

Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market

With oligonucleotides on the rise to treat rare diseases and cancers, Japanese manufacturer Nitto Denko is laying big plans.  Nitto will plug a whopping 25 billion yen ($225.93 million) into its Massachusetts-based subsidiary Nitto Denko Avecia, plus other companies in its fold, to beef up oligonucleotide production amid fast-growing demand. The cash will cover new buildings, a new commercial

Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market Read More »

AstraZeneca COVID-19 vaccine gets new Vaxzevria name, but is it enough to overcome rollout imbroglio?

AstraZeneca’s COVID-19 vaccine has an official name, Vaxzevria, now approved in Europe. But is a new name enough to hurdle its rollout communication glitches and now wavering vaccine confidence? Probably not on its own. However, some do see another hope on the horizon for AstraZeneca’s vaccine—the FDA. AZ plans to apply for FDA emergency use authorization

AstraZeneca COVID-19 vaccine gets new Vaxzevria name, but is it enough to overcome rollout imbroglio? Read More »

AstraZeneca’s COVID vaccine faces new round of restrictions—even after the EMA’s renewed backing

Several countries stopped using AstraZeneca’s COVID-19 shot earlier this month after reports of rare blood clots following vaccination. The European Medicines Agency sought to add clarity to the issue after an urgent safety review, but now regulators are slapping a fresh batch of restrictions on the shot. Even after the European Medicines Agency endorsed the shot’s overall profile two weeks

AstraZeneca’s COVID vaccine faces new round of restrictions—even after the EMA’s renewed backing Read More »

GlaxoSmithKline sells off $155M Zantac plant in India to Hetero Labs for a fraction of its cost

Three years ago, when it opened a $155 million plant in Vemgal, India, GlaxoSmithKline was anticipating a strong market for its gastroenterology treatments.  But ultimately all the move did was give GSK heartburn. On Tuesday, its board of directors approved a sale of the manufacturing facility to Hetero Labs of India for $25 million, a fraction

GlaxoSmithKline sells off $155M Zantac plant in India to Hetero Labs for a fraction of its cost Read More »

Longtime Gilead captain John Martin, mastermind of lifesaving HIV, hep C drugs, has died

John Martin, Ph.D., the CEO who shaped Gilead Sciences into the antiviral giant that it is today, has passed away. Gilead announced Martin’s death early Wednesday. He was the California drugmaker’s chief executive from 1996 to 2016 before moving to an executive chairman role, where he served until the end of 2018. “John’s legacy will

Longtime Gilead captain John Martin, mastermind of lifesaving HIV, hep C drugs, has died Read More »

Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches

As Daiichi Sankyo and Sanofi both chip in on production of other pharmas’ COVID-19 shots, the companies are calling it quits on their own, separate vaccine alliance in Japan.  Daiichi Sankyo is axing its marketing pact with Sanofi for its Squarekids combination vaccine and terminating a development deal for the pentavalent combination shot VN-0105 after encountering a

Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches Read More »

Merck CEO Frazier joins army of black execs speaking out on restrictive voting-rights laws

Merck CEO Kenneth Frazier may be on his way out the drugmaker’s door, but his impending retirement isn’t dampening his desire to speak out against injustice—and to urge other top executives to do the same. Frazier is among a large group of African American executives protesting a voting-rights law passed last week in Georgia. The

Merck CEO Frazier joins army of black execs speaking out on restrictive voting-rights laws Read More »

Pfizer finds Covid vaccine safe and effective for children 12 to 15

Pfizer plans to seek emergency approval for its Covid vaccine in younger people after a US trial found the jab prevented the disease and was “well-tolerated” in 12- to 15-year-olds. The US pharmaceutical company, which partnered with the German firm BioNTech to manufacture the vaccine, said it would submit the trial data to the US

Pfizer finds Covid vaccine safe and effective for children 12 to 15 Read More »

Pumped by a big year for its flu shots, Sanofi lays out €600M for new vaccine manufacturing plant

Sanofi may not be at the forefront in COVID-19 vaccines, but in influenza, it’s the biggest player—and as of now, getting even bigger. The French drugmaker plans to splash out €600 million to build a new flu vaccine factory in Toronto to increase supply of its Fluzone High-Dose vaccine. The plant will turn out the vaccine,

Pumped by a big year for its flu shots, Sanofi lays out €600M for new vaccine manufacturing plant Read More »

Scroll to Top